Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Piperlongumine

Piperlongumine (Piplartine) · also known as Piperlongumine, Piplartine, Piplartine

In cell experiments, piperlongumine can preferentially kill some senescence-induced cells, and its target is still under study. Selective clearance in humans has not been confirmed, and no validated oral pulse regimen exists.

Typical dose: A common pulse regimen is 100–300 mg/day, taken continuously for 2–3 days every quarter or every month. However, this regimen lacks validated human evidence for dose, safety and clearance effect, and should not be treated as routine advice.
Absorption and forms: Piperlongumine is a lipophilic alkaloid. There is no reliable evidence on whether taking it with a fatty meal improves absorption. Intermittent pulse dosing also has no basis validated in humans.

Mechanisms of action

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★★☆☆Mechanism evidence: grade CSecondary target

In mice, intraperitoneal piperlongumine can suppress NF-κB signaling in the brain after an inflammatory stimulus, which is a different exposure from oral supplementation. No reliable study has examined whether it suppresses the inflammatory factors secreted by senescent cells (SASP) in humans.

References (2)
  1. Gu et al. 2018 · Mouse study: intraperitoneal dosing inhibited NF-κB signaling in the brain after inflammatory stimulation
  2. Literature search found no direct study · Conclusion: no reliable study has shown NF-κB activity directly inhibited in humans at usual oral doses

Apoptosis-driven clearance of senescent cells (senolytic activity)

★★☆☆☆Mechanism evidence: grade DPrimary target

In some senescent-cell experiments, piperlongumine can preferentially kill senescent cells, and related studies suggest that OXR1, among other factors, may be involved. The mechanism and specific targets of selective clearance are not yet fully established, and there is no reliable study of clearance in humans after oral intake.

References (2)
  1. Wang et al. 2016 · Human fibroblast study: piperlongumine preferentially killed some senescence-induced cells
  2. 2018 · Cell mechanism study: OXR1 identified as a potential target; no reliable human study of senescent-cell clearance has been found yet

Safety and drug interactions

Piperlongumine is still at an early, experimental stage of research, and human safety data are lacking. Not recommended for pregnant women, breastfeeding women, or people with severe liver or kidney impairment. People who choose to try it should also avoid continuous long-term use.
Open in the interactive app ›